Trials and treatments developed with our support
Drugs in development or marketed with the support of AFM-Telethon concern neurological and neuromuscular diseases, diseases of the liver, vision, skin and immune system.
Do a search on the AFM-Telethon website.
Drugs in development or marketed with the support of AFM-Telethon concern neurological and neuromuscular diseases, diseases of the liver, vision, skin and immune system.
The impossible becomes possible! Thanks to the momentum of the Telethon and the work of researchers, a true scientific and medical revolution has begun and the first victories against rare diseases - previously incurable - have been won.
Documents to discover everything about the latest progress in research for a given disease or group of diseases. See the publications in English.
AFM-Telethon wanted to formalise the objectives that clinical study protocols should pursue and the points of attention they call for concerning organisational and methodological aspects. This formalisation should help AFM members in their participation in protocols.
You are now on a website that is edited by the French Muscular Dystrophy Association (AFM-Téléthon), a 1901 law association of public utility. Its headquarters are based in Paris : AFM-Institut de Myologie, 47-83 boulevard de l’Hôpital, 75651 Paris Cedex 13.
From formerly unknown diseases to conquered diseases, a medical revolution is underway and victories are multiplying.
Find here information on diseases : advances of research booklets presenting the lastest information on a given disease or group of diseases, information on trials and access to the Myobase portal.
AFM-Telethon has long struggled to defend the rights of patients, of people living with disabilities, and to obtain recognition for rare diseases. As a driver of research and innovation, it defends an ambitious national policy.
Committed to scientific research as well as to the support of patients and their families, AFM-Telethon acts independently, guided only by the urgency of the progressive disease, for the benefit of patients.
Transparent and meticulous management: in 2021, AFM-Telethon committed €80.8 M to its social missions, in addition to €4.9 M in advances and investment for the Cure mission.
The AFM-Telethon has chosen to implement a strategy of public interest to benefit as many people as possible.
While the first gene therapy drugs are obtaining marketing authorization and being made available to patients, the challenge of industrializing their production is a crucial one.
Created in 1987 at the initiative of Bernard Barataud and Pierre Birambeau, both fathers of sons suffering grom Duchenne muscular dystrophy, the Telethon combines, since its first edition, a TV program and dozen of thousands of events throughout France. Discover the birth of this unique fundraising event.
Peeling an apple. Lifting your arms. Walking. Smiling. Breathing. These routine actions use muscles and we accomplish them without thinking. But with neuromuscular diseases, the muscles are attacked and movement is prevented. In order to better treat them, AFM-Telethon wants to make myology a separate discipline.
Since 1987, the Telethon is a nearly thirty hours TV program broadcasted on the France Télévisions' channels. Discover all the ingrediants of the TV show.